12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abstral fentanyl regulatory update

FDA extended by three months the PDUFA date of June 4 for an NDA from ProStrakan for Abstral fentanyl to treat breakthrough cancer pain in patients already...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >